目的 分析重庆市南岸区含白喉-破伤风-无细胞百日咳（diphtheria, tetanus and acellular pertussis, DTaP）成分联合疫苗预防接种的安全性。方法 通过中国疾病预防控制中心免疫规划信息管理系统和重庆市免疫规划信息管理系统，收集重庆市南岸区2020—2024年报告的接种含DTaP成分联合疫苗的疑似预防接种异常反应（adverse event following immunization, AEFI）监测数据和疫苗接种数据。结果 2020—2024年重庆市南岸区累计接种含DTaP成分联合疫苗191 299剂次，报告296例AEFI，AEFI报告发生率为154.73/10万剂；其中一般反应291例（发生率152.12/10万剂）、异常反应5例（发生率2.61/10万剂）；男女性别比为1.33∶1.00；18~24月龄儿童占70.95%；各月均有病例报告，主要在4—9月，占78.38%；加强免疫的AEFI报告发生率高于基础免疫，且差异有统计学意义（χ²趋势= 266.21，P＜0.01）。结论 2020—2024年重庆市南岸区含DTaP成分联合疫苗接种的AEFI报告以一般反应为主，异常反应罕见，表明该疫苗具有良好的安全性。

Objective To evaluate the safety of combination vaccines containing diphtheria, tetanus, and acellular pertussis (DTaP) components in Nan’an District, Chongqing.Methods Data on adverse events following immunization (AEFI) reported for DTaP-containing combination vaccines and corresponding vaccination data in Nan’an District, Chongqing from 2020 to 2024 were collected through the Immunization Program Information Management System of the Chinese Center for Disease Control and Prevention and the Chongqing Immunization Program Information Management System.Results From 2020 to 2024, a total of 191 299 doses of DTaP-containing combination vaccines were administered in Nan’an District, Chongqing, with 296 AEFI cases reported. The reported AEFI rate was 154.73 per 100 000 doses. Among these, 291 cases were general reactions (152.12 per 100 000 doses) and 5 cases were abnormal reactions (2.61 per 100 000 doses). The male-to-female ratio was 1.33∶1.00. Children aged 18-24 months accounted for 70.95% of cases. Cases were reported throughout the year, with the majority (78.38%) occurring from April to September. The reported AEFI incidence rate for booster doses was higher than that for primary immunization, and the difference was statistically significant (χ²trend = 266.21, P < 0.01).Conclusion From 2020 to 2024, AEFI reports for DTaP-containing vaccines in Nan’an District, Chongqing are predominantly general reactions, with rare abnormal reactions, indicating that these vaccines have a favorable safety profile.